MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness (FuncProst)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by Oslo University Hospital.
Recruitment status was Recruiting
Information provided by (Responsible Party):
Therese Seierstad, Oslo University Hospital
First received: October 31, 2011
Last updated: November 2, 2011
Last verified: October 2011
The purpose of the study is to combine and correlate data from morphological and functional MRI, molecular signatures of tumor hypoxia, the presence of micrometastases and tumor hypoxia with the goal being predicting of prostate cancer aggressiveness.
Genital Neoplasms, Male
||Observational Model: Cohort
Time Perspective: Prospective
Biospecimen Retention: Samples With DNA
Blood, bone marrow, lymph nodes, prostate tissue
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||December 2013 (Final data collection date for primary outcome measure)
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Prostate cancer patients referred for surgical treatment.
- Patients suitable for surgery with confirmed prostate cancer, Gleason grade ≥ 3
- Patient has received no prior treatment for prostate cancer.
- Patient has adequate renal function: Estimated creatinine clearance ≥ 60 ml/minute.
- Patient must sign written informed consent according to the protocol approved by the Regional Ethics Committee.
- Patient with contraindication to MR or MR contrast media according to clinical practice.
- Patients who want to withdraw for any reason during the study.
- Patients previously undergone pelvic surgery or radiation therapy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01464216
|Oslo University Hospital
|Oslo, Norway, 0310 |
|Contact: Therese Seierstad, phD +4746451987 Therese.Seierstad@rr-research.no |
|Principal Investigator: Therese Seierstad, phD |
|Principal Investigator: Knut Håkon Hole, MD |
|Principal Investigator: Karol Axcrona, phD |
Oslo University Hospital
No publications provided
||Therese Seierstad, Head of Research, Department of Radiology and Nuclear Medicine, Oslo University Hospital
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 31, 2011
||November 2, 2011
||Norway:National Committee for Medical and Health Research Ethics
Norway: Institutional Scientific Board
Keywords provided by Oslo University Hospital:
Functional Magnetic Resonance Imaging
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 10, 2014
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male